• Home »
• Technologie »
• Vapeur de peroxyde d’hydrogène »
• Scientific references

Scientific references

The efficacy and ease-of-use of Bioquell's hydrogen peroxide vapour technology has been proven time and time again in leading peer-reviewed scientific publications. Below is a comprehensive list of the references to these articles.

Papers relating to Bioquell hydrogen peroxide vapour (HPV)
(generated from 30%-35% w/w hydrogen peroxide solution)

Andersen BM. Does 'airborne' hydrogen peroxide kill Mycobacterium tuberculosis? J Hosp Infect 2010 in press.

Lawley TD, Clare S, Deakin LJ, Goulding D, Yen JL, Raisen C, Brandt C, Lovell J, Cooke F, Clark TG, Dougan G. Purified Clostridium difficile spores facilitate the evaluation of healthcare disinfection regimens. Appl Environ Microbiol 2010;76:6895-8900.

Otter JA, Yezli S. A call for clarity when discussing hydrogen peroxide vapour and aerosol systems. J Hosp Infect, in press.

Otter JA, Havill NL, Boyce JM. Hydrogen peroxide vapor is not the same as aerosolized hydrogen peroxide. Infect Control Hosp Epidemiol 2010;31:1201-1202.

Otter JA, Yezli S, Schouten MA, van Zanten ARH, Houmes-Zielman G, Nohlmans-Paulssen. Hydrogen peroxide vapor (HPV) decontamination of an intensive care unit to remove environmental reservoirs of multidrug-resistant Gram-negative rods during an outbreak. Am J Infect Control 2010;38:754-756.

Otter JA, Barnicoat M, Down J, Smyth D, Yezli S, Jeanes A. Hydrogen peroxide vapor (HPV) decontamination of an intensive care unit room used to treat a patient with Lassa fever. J Hosp Infect 2010;75:335-337.

Otter JA, Yezli S. Cycle times for hydrogen peroxide vapour decontamination. Can J Microbiol 2010;56:356-257.

Pottage T, Richardson C, Parks S, Walker JT, Bennett AM. Evaluation of hydrogen peroxide gaseous disinfection systems to decontaminate viruses. J Hosp Infect 2010;74:55-61.

Otter JA, Puchowicz M, Ryan D, Salkeld JA, Cooper TA, Havill NL, Tuozzo K, Boyce JM. Feasibility of routinely using hydrogen peroxide vapor to decontaminate rooms in a busy United States hospital. Infect Control Hosp Epidemiol 2009;30:574-547.

Otter JA, Budde-Niekiel A. Hydrogen peroxide vapor: a novel method for the environmental control of lactococcal bacteriophages. J Food Prot 2009;72:412-414.

Otter JA, French GL. Survival of nosocomial bacteria and spores on surfaces and inactivation by hydrogen peroxide vapour (HPV). J Clin Microbiol 2009;47:205-207.

Unger-Bimczok B, Kottke V, Hertel C, Rauschnabel J. The Influence of Humidity, Hydrogen Peroxide Concentration, and Condensation on the Inactivation of Geobacillus stearothermophilus Spores with Hydrogen Peroxide Vapor. J Pharm Innov 2008;3:123-33.

Boyce JM, Havill NL, Otter JA, McDonald LC, Adams NM, Thompson A, Wiggs L, Noble-Wang J. Impact of hydrogen peroxide vapor room bio-decontamination on environmental contamination and nosocomial transmission of Clostridium difficile. Infect Cont Hosp Epidemiol 2008;29:723-729.

Dryden M, Parnaby R, Dailly S, Lewis T, Davis-Blues K, Otter JA, Kearns AM.Hydrogen peroxide vapor (HPV) decontamination in the control of a polyclonal MRSA outbreak on a surgical ward. J Hosp Infect 2008;68:190-192.

Hall L, Otter JA, Chewins J, Wengenack NL. Deactivation of the dimorphic fungi Histoplasma capsulatum, Blastomyces dermatitidis and Coccidioides immitis using hydrogen peroxide vapor. Med Mycol 2008;46:189-191.

Otter JA, Chewins C, Windsor D, Windsor H. Microbial contamination in cell culture: a potential role for hydrogen peroxide vapour (HPV)? Cell Biol Int 2008;32:326-327.

Otter JA, Cummins M, Ahmad F, van Tonder C, Drabu YJ. Assessing the biological efficacy and rate of recontamination following hydrogen peroxide vapour decontamination. J Hosp Infect 2007;67:182-188.

Hall L, Otter JA, Chewins J, Wengenack NL. Use of hydrogen peroxide vapour for deactivation of Mycobacterium tuberculosis in a biological safety cabinet and a room. J Clin Microbiol 2007;45:810-815.

Hardy KJ, Gossain S, Henderson N, Drugan C, Oppenheim BA, Gao F et al. Rapid recontamination with MRSA of the environment of an intensive care unit after decontamination with hydrogen peroxide vapour. J Hosp Infect 2007;66:360-368.

Boyce JM. Environmental contamination makes an important contribution to hospital infection. J Hosp Infect 2007; 65 Suppl 2:S50-54.

Otter JA, French GL, Adams NM, Watling D, Parks MJ. Hydrogen peroxide vapour decontamination in an overcrowded tertiary care referral centre: some practical answers. J Hosp Infect 2006;62:384-385.

Rogers JV, Sabourin CL, Choi YW, Richter WR, Rudnicki DC, Riggs KB et al. Decontamination assessment of Bacillus anthracis, Bacillus subtilis, and Geobacillus stearothermophilus spores on indoor surfaces using an HPV generator. J Appl Microbiol 2005;99:739-748.

Bates CJ, Pearse R. Use of hydrogen peroxide vapour for environmental control during a Serratia outbreak in a neonatal intensive care unit. J Hosp Infect 2005;61:364-366

Otter JA. Bio-deactivation of hospital pathogens. Health Estate 2005;59:41-44.

Johnston MD, Lawson S, Otter JA. Evaluation of hydrogen peroxide vapour as a method for the decontamination of surfaces contaminated with Clostridium botulinum spores. J Microbiol Methods 2005;60:403-411.

French GL, Otter JA, Shannon KP, Adams NM, Watling D, Parks MJ. Tackling contamination of the hospital environment by methicillin-resistant Staphylococcus aureus (MRSA): a comparison between conventional terminal cleaning and hydrogen peroxide vapour decontamination. J Hosp Infect 2004;57:31-37.

Watling D, Ryle C, Parks M, Christopher M. Theoretical analysis of the condensation of hydrogen peroxide gas and water vapour as used in surface decontamination. PDA J Pharm Sci Technol 2002;56:291-299.

Conference abstracts relating to Bioquell HPV

Goyal SM, Chander Y, Yezli S, Otter JA. Hydrogen peroxide vapor (HPV) inactivation of feline calicivirus, a surrogate for norovirus. 7th Hospital Infection Society International Conference, 10-13 October 2010, Liverpool, UK.

Otter JA, Barnicoat M, Down J, Smyth D, Yezli S, Jeanes A. Hydrogen peroxide vapor (HPV) decontamination of an intensive care unit room used to treat a patient with Lassa fever. 7th Hospital Infection Society International Conference, 10-13 October 2010, Liverpool, UK.

Otter JA, Yezli S, Bissell D. Hydrogen peroxide vapour (HPV) decontamination: a novel technology for the control of hospital acquired infections. Australian Infection Control Association Conference, 4-6 October 2010, Perth, Australia.

Adams NMT, Yezli S, Otter JA. Hydrogen peroxide vapour decontamination: a versatile method to tackle biological warfare agents and pathogens associated with hospital-acquired infections. 10th International Symposium on Protection Against Chemical and Biological Warefare Agents, 8-11 June 2010, Stockholm, Sweden. 

Otter JA, Duclos M, Salkeld JAG, Nowakowski E, Passaretti CL, Perl TM. Decontamination of unused, packaged supplies contaminated with vancomycin-resistant enterococci (VRE) using hydrogen peroxide vapor (HPV). 5th Decennial Meeting of the Society for Healthcare Epidemiology of America (SHEA), Atlanta, GA, USA. Abstract 62. [Oral*] (Also presented at the Birmingham International Burns Congress, 5-7 September 2010, Birmingham UK. Abstract 13. [Poster].)

Manain F, Griesenauer S, Senkel D. Impact of an intensive terminal cleaning and disinfection (C/D) protocol involving selected hospital rooms on endemic nosocomial infection (NI) rates of common pathogens at a tertiary care medical center. 5th Decennial Meeting of the Society for Healthcare Epidemiology of America (SHEA), Atlanta, GA, USA. Abstract LB6. [Oral]

Manain F, Griesenauer S, Senkel D. Persistence of Acinetobacer baumannii complex (ABC) and methicillin-resistant Staphylococcus aureus (MRSA) in hospital rooms despite 4 rounds of terminal cleaning and disinfection (C/D): exploring a new strategy. 5th Decennial Meeting of the Society for Healthcare Epidemiology of America (SHEA), Atlanta, GA, USA. Abstract LB7. [Poster]

Donnegan NE. Vaporized Hydrogen Peroxide as a part of a control intervention during an outbreak of Acinetobacter in an ICU. Abstract 207. [Poster]

Yezli S, Millward L, Salkeld JAG, Park MJ, Otter JA. Routine use of hydrogen peroxide vapour decontamination in the NHS. Infection Prevention Society Annual Meeting. Harrogate, 2009. [Poster]

Cooper T, O’Leary M. Clinical impact and cost-benefit of routine, preventative HPV bio-decontamination in a UK hospital. Infection Prevention Society Annual Meeting. Harrogate, 2009. [Poster]

Passaretti CL­, Otter JA, Lipsett P, Shangraw A, Myers J, Ross T, Carroll K, Perl TM. Adherence to Hydrogen Peroxide Vapor (HPV) decontamination reduces VRE acquisition in high-risk units. 48^th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)and the Infectious Diseases Society of America (IDSA). Washington DC, USA, 2008. Abstract K4124b. [Poster]

Otter JA, Davies B, Klein J, Watts T, Kearns AM, French GL. Identification and control of an outbreak of gentamicin-resistant, methicillin-susceptible Staphylococcus aureus on a neonatal unit. 13^th International Symposium on Staphylococci and Staphylococcal Infection (ISSSI), Cairns, Australia, 2008. [Oral]

Passaretti CL­, Lipsett P, Otter JA, Speck K, Lee A, Ryan D, Salkeld JAG, Adams NMT, Ristaino P, Maragakis L, Ross T, Carroll K, Perl TM. Does hydrogen peroxide vapor (HPV) enhance decontamination for multidrug-resistant organisms (MDROs) in intensive care units (ICUs)? 18^th Annual Meeting of the Society for Healthcare Epidemiology of America (SHEA), Orlando, Florida, 2008. Abstract 177. [Poster]

Puchowicz M, Ryan D, Otter JA, Salkeld JAG, Cooper TA, Havill NL, Tuozzo K, Boyce JM. Feasibility of ongoing use of hydrogen peroxide vapor (HPV) technology to decontaminate rooms vacated by patients with multidrug-resistant organisms. 18^th Annual Meeting of the Society for Healthcare Epidemiology of America (SHEA), Orlando, Florida, 2008. [Poster]

Dryden M, Parnaby R, Dailly S, Lewis T, Davis-Blues K, Otter JA, Kearns AM.Environmental decontamination with hydrogen peroxide vapor (HPV) in the control of an MRSA outbreak. 47^th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 2007, Chicago. [Poster]

Otter JA, Cummins M, Ahmad F, van Tonder C, Drabu Y. O19 Assessing the biological efficacy and rate of recontamination following hydrogen peroxide vapour decontamination. Int J Antimicrob Agents 2007;29 Suppl. 2:S4. (16^th Annual Meeting of the European Congress of Clinical Microbiology and Infectious Disesase (ECCMID)) [Oral]

Schouten M, Otter JA, van Zanten A, Houmes-Zielman G, Nohlmans-Paulssen M. P1692 Environmental decontamination of an intensive care unit to control outbreaks of multidrug-resistant Gram-negative rods using hydrogen peroxide vapour. Int J Antimicrob Agents 2007;29 Suppl. 2:S479. (16^th Annual Meeting of the European Congress of Clinical Microbiology and Infectious Disesase (ECCMID)) [Poster]

Boyce JM, Havill NL, Otter JA, McDonald LC, Adams NM, Thompson A, Wiggs L, Noble-Wang J. Impact of Hydrogen Peroxide Vapor Room Bio-Decontamination on Environmental Contamination and Nosocomial Transmission of Clostridium difficile. 16^th Annual Meeting of the Society for Healthcare Epidemiology of America (SHEA), Chicago, Illinois, 2006. Abstract 155. [Oral]

Hall L, Otter JA, Chewins J, Wengenack NL. Use of hydrogen peroxide vapour for deactivation of Mycobacterium tuberculosis in a biological safety cabinet and a room. 105^th General Meeting of the American Society for Microbiology (ASM), Orlando, Florida, 2006. [Poster]

Hall L, Otter JA, Chewins J, Wengenack NL. Deactivation of dimorphic fungi using HPV. 16^th Congress of the International Society of Human and Animal Mycology (ISHAM), Paris, France, 2006. [Poster]

French GL, Shannon KP, Otter JA. Survival of nosocomial bacteria dried in air and killing by hydrogen peroxide vapour (HPV). 44^th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington DC, 2004. [Poster]

Other documents relating to Bioquell HPV

Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-455.

UK Department of Health and Health Protection Agency. Clostridium difficile infection: how to deal with the problem. 2009. Available from http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_093220

UK Department of Health and NHS Purchasing and Supply Agency. HCAI Technology Innovation Programme. Showcase Hospitals report number 3. The Bioquell Hydrogen Peroxide Vapour (HPV) Disinfection System. Available from www.clean-safe-care.nhs.uk. 2009.

Rutala WA, Weber DJ and the Healthcare Infection Control Practices Advisory Committee (HICPAC). Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008.

McAnoy AM. Vaporous Decontamination Methods: Potential Uses and Research Priorities for Chemical and Biological Contamination Control. Human Protection and Performance Division Defence Science and Technology Organisation. Department of Defence. Australian Government. 2006.

Healthcare Commission. Investigation into outbreaks of Clostridium difficile at Stoke Mandeville Hospital, Buckinghamshire Hospitals NHS Trust. July 2006.

Pellowe CM, Pratt RJ, Loveday HP, Harper P, Robinson N, Jones SRLJ. The epic project. Updating the evidence-base for national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England: a report with recommendations. Brit J Infect Control 2004;5:10-16.

UK case studies. Available at www.clean-safe-care.nhs.uk.